Lana Pine is the editor of HCPLive Rheumatology. She is an experienced editor and technical writer with a demonstrated history of working in the banking and publishing industries. In her free time, she enjoys cooking, yoga, listening to podcasts, and drawing. She can be reached via email at LPine@mjhlifesciences.com.
Biosimilars Month in Review: January 2024
February 4th 2024The biosimilars month in review explores the efficacy and safety of biosimilars in treating uveitis, highlights the FDA’s acceptance of a biologics license application for an ustekinumab biosimilar, and emphasizes the safety and accessibility benefits of biosimilars in rheumatic conditions.
Read More
Patients with RA Surprised by Positive Impact of Exercise on Sleep
February 3rd 2024Four themes emerged from the data, including the positive impact of exercise on sleep, positive experiences of the exercise intervention, mental health benefits, and achieving empowerment and ownership during the exercise process.
Read More
Quiz: ACR Clinical Guideline for the Treatment of Rheumatoid Arthritis
February 2nd 2024The 2021 ACR Guideline for the Treatment of Rheumatoid Arthritis provides updated recommendations for the pharmacologic management of RA. In honor of Rheumatoid Arthritis Awareness Day, test your knowledge with this quiz:
Read More
Targeting Mental Health, Pain-Related Illnesses May Improve Outcomes in Difficult to Treat RA
January 29th 2024The presence of mental health, pain-related illnesses, and metabolic diseases were significantly associated with the worsening of arthritis-related pain, severity, and disease activity.
Read More
Online Survey Reveals Perspectives, Desires for Understanding in Patients with Fibromyalgia
January 25th 2024Thematic analysis revealed common themes, including uncertainty about the cause of fibromyalgia, feelings of invisibility, confusion about symptoms and flares, and a strong desire for more accessible treatment information.
Read More
On January 23, 2024, Heron Therapeutics announced the FDA had approved its sNDA for bupivacaine and meloxicam extended-release solution to expand the indication to include soft tissue and orthopedic surgical procedures, including procedures in which direct exposure to articular cartilage is avoided.
Read More
Initiation of ULT During Gout Flare Does Not Impact Severity, Duration
January 23rd 2024There were no differences in patient-rated pain scores, time to flare resolution, and the risk of recurrent flare in patients initiating urate-lowering therapy during treatment and those delaying treatment.
Read More